CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

– Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX – The post CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas appeared first on Bio Tech Winners.

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

LabNews Media LLC

labnews.ai 的主编是 Marita Vollborn 和 Vlad Georgescu。自 1994 年以来，他们一直是畅销书作家、科学作家和科学记者。更多关于他们的写作信息，请访问 X-Press Journalistenbüro (https://xpress-journalisten.com)。更多维基百科信息：关于 Marita：https://de.wikipedia.org/wiki/Marita_Vollborn 关于 Vlad：https://de.wikipedia.org/wiki/Vlad_Georgescu

查看完整简介